Pfizer Announces FDA Will No Longer Require Warning Label for Its Chantix Medication

Pfizer announced that the FDA will no longer require the company’s smoking-cessation pill Chantix to carry a warning about a potential link to suicide, depression and hostile behavior.

In addition, the label can now also state that Chantix works better than the nicotine patch and a generic smoking-cessation pill known as bupropion.

The FDA made its decision based on results from an 8,144-subject study probing the safety of Chantix and bupropion, sponsored by Pfizer and GlaxoSmithKline. The study found results from an 8,144-subject study probing the safety of Chantix and bupropion, sponsored by Pfizer and GlaxoSmithKline.